Abstract | PURPOSE: METHODS:
ERbeta expression was monitored immunohistochemically in 56 cases of astrocytomas of all grades (grade I-IV) and in adjacent non-neoplastic brain tissue. RESULTS: Moderate or strong nuclear immunopositivity was obtained in non-neoplastic astrocytes and in low-grade astrocytomas, whereas the majority of high-grade tumors were immunonegative or displayed weak immunoreactivity. The progressive decline in ERbeta expression paralleled the increase in tumor grade. CONCLUSIONS: In as much as ERbeta is possibly the only ER expressed in astrocytes, its decreased expression may play an important role in astrocytic tumor initiation and in the potential response of glial neoplasms to tamoxifen.
|
Authors | Anna Batistatou, Dimitrios Stefanou, Anna Goussia, Evdokia Arkoumani, Athanasios G Papavassiliou, Niki J Agnantis |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 130
Issue 7
Pg. 405-10
(Jul 2004)
ISSN: 0171-5216 [Print] Germany |
PMID | 15141349
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Estrogen Receptor beta
|
Topics |
- Adolescent
- Adult
- Aged
- Astrocytoma
(chemistry, pathology)
- Biomarkers, Tumor
(analysis)
- Brain Chemistry
- Brain Neoplasms
(chemistry, pathology)
- Child
- Estrogen Receptor beta
(analysis)
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
- Male
- Middle Aged
- Predictive Value of Tests
|